AR039256A1 - Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos - Google Patents
Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentosInfo
- Publication number
- AR039256A1 AR039256A1 ARP030101184A ARP030101184A AR039256A1 AR 039256 A1 AR039256 A1 AR 039256A1 AR P030101184 A ARP030101184 A AR P030101184A AR P030101184 A ARP030101184 A AR P030101184A AR 039256 A1 AR039256 A1 AR 039256A1
- Authority
- AR
- Argentina
- Prior art keywords
- radical
- phenyl
- preparation
- alkyl radical
- application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Compuestos de fórmula general (1), así como a sus sales fisiológicamente aceptables, a los procedimientos para su preparación, a compuestos intermediarios para obtención, a la aplicación de los compuestos de fórmula general (1) como medicamentos en la prevención y tratamiento de trastornos del SNC, y a los composiciones farmacéuticas que los contienen. Reivindicación 1: Un compuesto derivado de benzoxazinona de fórmula (1) en la cual: R1 representa H, halógeno, alcoxilo o un radical alquilo C1-4; R2 representa H, un radical alquilo C1-4, un radical fenilo, un radical bencilo, o junto con R3 puede formar parte de un heterociclo de 5 o 6 miembros; R3 representa anillo bicíclico, anillo tricíclico, fenilo sustituido, o fenilo sustituido por una cadena hidrocarbonada que junto con R2 forma parte de un heterociclo nitrogenado de 5 o 6 miembros; A representa -CHR4- o -CHR4-CH2-, y R4 representa H, un radical alquilo C1-4 o un radical fenilo; o una de sus sales fisiológicamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200200813A ES2193875B2 (es) | 2002-04-09 | 2002-04-09 | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos. |
Publications (1)
Publication Number | Publication Date |
---|---|
AR039256A1 true AR039256A1 (es) | 2005-02-16 |
Family
ID=28686085
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030101184A AR039256A1 (es) | 2002-04-09 | 2003-04-04 | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos |
ARP030101235A AR048567A1 (es) | 2002-04-09 | 2003-04-08 | Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030101235A AR048567A1 (es) | 2002-04-09 | 2003-04-08 | Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas. |
Country Status (29)
Country | Link |
---|---|
US (3) | US7056914B2 (es) |
EP (2) | EP1497285B1 (es) |
JP (1) | JP2005529866A (es) |
KR (1) | KR20050008679A (es) |
CN (1) | CN1659164A (es) |
AR (2) | AR039256A1 (es) |
AT (2) | ATE489382T1 (es) |
AU (2) | AU2003222804A1 (es) |
BR (1) | BR0309083A (es) |
CA (1) | CA2481701A1 (es) |
DE (2) | DE60335094D1 (es) |
DK (1) | DK1500654T3 (es) |
EC (1) | ECSP045353A (es) |
ES (3) | ES2193875B2 (es) |
HK (1) | HK1069820A1 (es) |
HR (1) | HRP20040919A2 (es) |
IL (1) | IL164442A0 (es) |
IS (1) | IS7491A (es) |
MA (1) | MA27692A1 (es) |
MX (1) | MXPA04009889A (es) |
NO (1) | NO20044322L (es) |
NZ (1) | NZ536167A (es) |
PL (1) | PL372537A1 (es) |
PT (1) | PT1500654E (es) |
RU (1) | RU2004133041A (es) |
TN (1) | TNSN04203A1 (es) |
UA (1) | UA79460C2 (es) |
WO (2) | WO2003084952A1 (es) |
ZA (1) | ZA200408275B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2193875B2 (es) * | 2002-04-09 | 2005-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos. |
ES2222833B1 (es) * | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos. |
ES2228268B1 (es) * | 2003-07-30 | 2006-07-01 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6. |
ES2228267B1 (es) * | 2003-07-30 | 2006-07-01 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6. |
WO2005090340A1 (ja) * | 2004-03-22 | 2005-09-29 | Banyu Pharmaceutical Co., Ltd. | ピペリジン-1-カルボキサミド誘導体 |
US8147853B2 (en) | 2005-02-15 | 2012-04-03 | The Procter & Gamble Company | Personal care compositions containing hydrophobically modified non-platelet particles |
WO2006102113A2 (en) * | 2005-03-21 | 2006-09-28 | The Procter & Gamble Company | Multi-phase personal care composition comprising visually distinct phases |
WO2006113118A1 (en) * | 2005-04-13 | 2006-10-26 | The Procter & Gamble Company | Structured multi-phased personal care composition comprising branched anionic surfactants |
US7820609B2 (en) | 2005-04-13 | 2010-10-26 | The Procter & Gamble Company | Mild, structured, multi-phase personal cleansing compositions comprising density modifiers |
ITMI20050909A1 (it) * | 2005-05-19 | 2006-11-20 | Acraf | Uso di un benzoil derivato dal 3-ammino-carbazolo per la produzione di un farmaco per il trattamento di un disturbo associato alla produzione di prostaglandina e2-pge2- |
US20120015009A9 (en) * | 2005-06-07 | 2012-01-19 | The Procter & Gamble Company | Multi-phased personal care composition comprising a blooming perfume composition |
ITMI20051523A1 (it) * | 2005-08-03 | 2007-02-04 | Acraf | Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo |
WO2007066310A2 (en) * | 2005-12-08 | 2007-06-14 | The Procter & Gamble Company | A container comprising an in-mold label positioned proximate to a surface topography |
US20070167338A1 (en) * | 2006-01-09 | 2007-07-19 | Mchugh Colin M | Multiphase personal care compositions comprising beads |
US8104616B2 (en) | 2006-02-11 | 2012-01-31 | The Procter & Gamble Company | Clamshell package for holding and displaying consumer products |
US8153144B2 (en) * | 2006-02-28 | 2012-04-10 | The Proctor & Gamble Company | Stable multiphase composition comprising alkylamphoacetate |
WO2008020455A2 (en) * | 2006-08-14 | 2008-02-21 | Council Of Scientific & Industrial Research | Pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation thereof |
EP1902733A1 (en) * | 2006-09-19 | 2008-03-26 | Laboratorios Del Dr. Esteve, S.A. | Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity |
CL2007003044A1 (es) * | 2006-10-24 | 2008-07-04 | Wyeth Corp | Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros. |
US20090028809A1 (en) * | 2007-07-27 | 2009-01-29 | Jonathan Robert Cetti | Personal care article for sequentially dispensing compositions with variable concentrations of hydrophobic benefit materials |
US20090028808A1 (en) * | 2007-07-27 | 2009-01-29 | The Procter & Gamble Company | Personal care article for sequentially dispensing compositions with variable concentrations of partitioned benefit or suspended benefit agents |
US20090029900A1 (en) * | 2007-07-27 | 2009-01-29 | The Procter & Gamble Company | Personal care article for sequentially dispensing compositions with distinct fragrance characters |
US7733945B2 (en) * | 2008-03-18 | 2010-06-08 | On-Ramp Wireless, Inc. | Spread spectrum with doppler optimization |
US20090275574A1 (en) * | 2008-05-05 | 2009-11-05 | Astrazeneca Ab | Novel compounds-300 |
JP5642661B2 (ja) * | 2009-03-05 | 2014-12-17 | 塩野義製薬株式会社 | Npyy5受容体拮抗作用を有するピペリジンおよびピロリジン誘導体 |
CN110684043B (zh) * | 2019-08-13 | 2022-09-06 | 温州大学 | 一种c-n轴手性芳胺化合物及其制备方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU691829B2 (en) * | 1993-07-16 | 1998-05-28 | Merck & Co., Inc. | Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists |
EP0755392A4 (en) | 1994-04-14 | 1997-05-02 | Merck & Co Inc | ALPHA1C ADRENERGIC RECEPTOR ANTAGONISTS |
WO1997019682A1 (en) | 1995-12-01 | 1997-06-05 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
AU7692996A (en) | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Receptor antagonists |
AU1698997A (en) | 1996-01-16 | 1997-08-11 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
CA2249601A1 (en) | 1996-04-03 | 1997-10-23 | Thorsten E. Fisher | Inhibitors of farnesyl-protein transferase |
AU5135998A (en) | 1996-12-03 | 1998-06-29 | Banyu Pharmaceutical Co., Ltd. | Novel urea derivatives |
CA2251368A1 (en) | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amide derivatives as selective neuropeptide y receptor antagonists |
AU6309698A (en) | 1997-03-12 | 1998-09-29 | Banyu Pharmaceutical Co., Ltd. | Drugs containing aminopyridine derivatives as the active ingredient |
US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
ATE284861T1 (de) | 1998-10-07 | 2005-01-15 | Ortho Mcneil Pharm Inc | N-aralkylaminotetraline als neuropeptid-y-y5- rezeptorliganden |
WO2001007409A1 (en) | 1999-07-23 | 2001-02-01 | Astrazeneca Uk Limited | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
AU769081B2 (en) | 1999-08-26 | 2004-01-15 | Bristol-Myers Squibb Company | NPY antagonists: spiroisoquinolinone derivatives |
SE9904652D0 (sv) * | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
AU2001246494A1 (en) | 2000-03-03 | 2001-09-12 | Novartis Ag | Condensed thiazolamines and their use as neuropeptide y5 antagonists |
WO2002094825A1 (fr) | 2001-05-22 | 2002-11-28 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de spiropiperidine |
JP4341404B2 (ja) * | 2001-08-07 | 2009-10-07 | 萬有製薬株式会社 | スピロ化合物 |
ES2193875B2 (es) * | 2002-04-09 | 2005-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos. |
-
2002
- 2002-04-09 ES ES200200813A patent/ES2193875B2/es not_active Expired - Fee Related
-
2003
- 2003-04-04 AR ARP030101184A patent/AR039256A1/es not_active Application Discontinuation
- 2003-04-04 US US10/407,343 patent/US7056914B2/en not_active Expired - Fee Related
- 2003-04-08 KR KR10-2004-7016130A patent/KR20050008679A/ko not_active Application Discontinuation
- 2003-04-08 EP EP03718741A patent/EP1497285B1/en not_active Expired - Lifetime
- 2003-04-08 MX MXPA04009889A patent/MXPA04009889A/es active IP Right Grant
- 2003-04-08 CA CA002481701A patent/CA2481701A1/en not_active Abandoned
- 2003-04-08 US US10/409,235 patent/US7041665B2/en not_active Expired - Fee Related
- 2003-04-08 PL PL03372537A patent/PL372537A1/xx not_active Application Discontinuation
- 2003-04-08 DE DE60335094T patent/DE60335094D1/de not_active Expired - Lifetime
- 2003-04-08 JP JP2003582149A patent/JP2005529866A/ja active Pending
- 2003-04-08 ES ES03718741T patent/ES2356815T3/es not_active Expired - Lifetime
- 2003-04-08 IL IL16444203A patent/IL164442A0/xx unknown
- 2003-04-08 CN CN038128853A patent/CN1659164A/zh active Pending
- 2003-04-08 AT AT03718741T patent/ATE489382T1/de not_active IP Right Cessation
- 2003-04-08 NZ NZ536167A patent/NZ536167A/en unknown
- 2003-04-08 RU RU2004133041/04A patent/RU2004133041A/ru not_active Application Discontinuation
- 2003-04-08 WO PCT/EP2003/003629 patent/WO2003084952A1/en active Application Filing
- 2003-04-08 AR ARP030101235A patent/AR048567A1/es not_active Application Discontinuation
- 2003-04-08 AU AU2003222804A patent/AU2003222804A1/en not_active Abandoned
- 2003-04-08 BR BR0309083-3A patent/BR0309083A/pt not_active IP Right Cessation
- 2003-04-09 PT PT03712152T patent/PT1500654E/pt unknown
- 2003-04-09 ES ES03712152T patent/ES2258219T3/es not_active Expired - Lifetime
- 2003-04-09 DK DK03712152T patent/DK1500654T3/da active
- 2003-04-09 AU AU2003216934A patent/AU2003216934A1/en not_active Abandoned
- 2003-04-09 EP EP03712152A patent/EP1500654B1/en not_active Expired - Lifetime
- 2003-04-09 AT AT03712152T patent/ATE316966T1/de not_active IP Right Cessation
- 2003-04-09 DE DE60303440T patent/DE60303440T2/de not_active Expired - Lifetime
- 2003-04-09 WO PCT/ES2003/000162 patent/WO2003084939A1/es not_active Application Discontinuation
- 2003-08-04 UA UA20041109155A patent/UA79460C2/uk unknown
-
2004
- 2004-10-05 HR HR20040919A patent/HRP20040919A2/hr not_active Application Discontinuation
- 2004-10-06 IS IS7491A patent/IS7491A/is unknown
- 2004-10-08 MA MA27902A patent/MA27692A1/fr unknown
- 2004-10-08 EC EC2004005353A patent/ECSP045353A/es unknown
- 2004-10-08 TN TNP2004000203A patent/TNSN04203A1/en unknown
- 2004-10-12 NO NO20044322A patent/NO20044322L/no not_active Application Discontinuation
- 2004-10-13 ZA ZA200408275A patent/ZA200408275B/en unknown
-
2005
- 2005-03-09 HK HK05102067.9A patent/HK1069820A1/xx not_active IP Right Cessation
-
2006
- 2006-01-24 US US11/338,363 patent/US7514429B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR039256A1 (es) | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos | |
AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
AR023971A1 (es) | Derivados de 4,5,6,7-tetrahidroindazol, procedimiento para la preparacion de los mismos y su utilizacion como agentes antitumorales | |
AR028810A1 (es) | Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion | |
ECSP055853A (es) | Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos | |
PA8591701A1 (es) | Derivados de pirrolopirimidina | |
AR053232A1 (es) | Derivados de piridina condensadas, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de agentes terapeuticos antiinflamatorios y para el tratamiento de enfermedades relacionadas con el sistema inmunologico. | |
AR064561A1 (es) | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. | |
AR054799A1 (es) | Derivados de oxindol | |
EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
AR038686A1 (es) | Formulaciones de derivados de androstano y agonistas del adrenoreceptor beta 2 antiinflamatorios | |
AR054524A1 (es) | Metodos y formas de dosificacion para reducir los efectos secundarios de compuestos de carbamato | |
CO5590895A2 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos | |
CL2004000848A1 (es) | Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras | |
UY27716A1 (es) | Derivados de nitrosodifenilamina y composiciones farmacéuticas que los comprenden como medicamentos que se pueden utilizar en el tratamiento de patologías que se caracterizan por estrés oxidativo. | |
ECSP066349A (es) | Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales | |
UY27338A1 (es) | Nuevos derivados de ácido sulfónico | |
UY27969A1 (es) | Formulaciones que comprenden un compuesto de indolinona | |
AR045155A1 (es) | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
AR050711A1 (es) | Derivados arilsulfonilestilbeno para el tratamiento y/o prevencion de afecciones del sistema nervioso central | |
ECSP22036502A (es) | Inhibidores del factor d del complemento para administraci?n oral | |
CO5590916A2 (es) | Dicetopiperacinas sustituidas como antagonistas de oxitocina | |
AR045156A1 (es) | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
AR057885A1 (es) | Acido 1-(1-(2- etoxietil) - 1- etil-7-(4- metilpiridin -2- ilamino)- 1h pirazolo (4,3-d) pirimidin -5- il) piperidina -4- carboxilico y las sales del mismo. composiciones farmaceuticas. | |
CY1112057T1 (el) | Θεραπευτικος παραγων για διαταραχη επαρκειας τροφης στο στομαχι |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |